Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells.

Kamio N, Kawato T, Tanabe N, Kitami S, Morita T, Ochiai K, Maeno M.

Connect Tissue Res. 2013;54(2):147-52. doi: 10.3109/03008207.2012.761978.

PMID:
23323745
2.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913
4.

Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.

Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.

Life Sci. 2007 Mar 13;80(14):1311-8. Epub 2007 Jan 23.

PMID:
17306833
5.

Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H, Tomomura A.

J Biol Chem. 2010 Aug 13;285(33):25448-57. doi: 10.1074/jbc.M109.068742. Epub 2010 Jun 14.

6.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

7.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

8.

Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).

Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T.

Immunol Lett. 2012 Feb 29;142(1-2):34-40. doi: 10.1016/j.imlet.2011.12.001. Epub 2011 Dec 13.

PMID:
22193059
9.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

10.

AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis.

Li CH, Zhao JX, Sun L, Yao ZQ, Deng XL, Liu R, Liu XY.

Biochem Biophys Res Commun. 2013 Jun 14;435(4):533-9. doi: 10.1016/j.bbrc.2013.04.084. Epub 2013 May 7.

PMID:
23665018
11.

Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.

Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.

PMID:
15752732
12.

[Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].

Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.

Zhonghua Yi Xue Za Zhi. 2004 Dec 17;84(24):2102-6. Chinese.

PMID:
15730627
13.

MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.

Kim JH, Kim K, Youn BU, Jin HM, Kim N.

Cell Signal. 2010 Sep;22(9):1341-9. doi: 10.1016/j.cellsig.2010.05.001. Epub 2010 May 11.

PMID:
20466061
14.

RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.

Iwai K, Koike M, Ohshima S, Miyatake K, Uchiyama Y, Saeki Y, Ishii M.

J Bone Miner Res. 2007 Oct;22(10):1612-20.

15.

The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.

Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.

Eur J Immunol. 2008 Jun;38(6):1598-609. doi: 10.1002/eji.200737650.

16.

Inhibitory effect of minocycline on osteoclastogenesis in mouse bone marrow cells.

Nagasawa T, Arai M, Togari A.

Arch Oral Biol. 2011 Sep;56(9):924-31. doi: 10.1016/j.archoralbio.2011.02.002. Epub 2011 Mar 5.

PMID:
21377143
17.

Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts.

Yonezawa T, Mase N, Sasaki H, Teruya T, Hasegawa S, Cha BY, Yagasaki K, Suenaga K, Nagai K, Woo JT.

J Cell Biochem. 2012 Feb;113(2):440-8. doi: 10.1002/jcb.23213.

PMID:
21678460
18.

Water extract of Cordyceps sinensis (WECS) inhibits the RANKL-induced osteoclast differentiation.

Mizuha Y, Yamamoto H, Sato T, Tsuji M, Masuda M, Uchida M, Sakai K, Taketani Y, Yasutomo K, Sasaki H, Takeda E.

Biofactors. 2007;30(2):105-16.

PMID:
18356582
19.

Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.

Mol Pharmacol. 2010 Jan;77(1):17-25. doi: 10.1124/mol.109.057877. Epub 2009 Oct 14.

20.

Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.

Kim WS, Kim HJ, Lee ZH, Lee Y, Kim HH.

Exp Cell Res. 2013 Feb 15;319(4):436-46. doi: 10.1016/j.yexcr.2012.12.004. Epub 2012 Dec 12.

PMID:
23246654

Supplemental Content

Support Center